← boardnext 2028-07-10next 2028-07-21next 2028-07-25next 2028-08-02next 2028-08-24next 2028-09-14next 2028-09-25next 2028-09-29next 2028-09-30next 2028-10-31next 2028-11-01next 2028-11-08next 2028-11-24next 2028-11-27next 2028-11-29next 2028-12-08next 2028-12-21next 2029-02-17next 2029-03-23next 2029-04-16next 2029-06-15next 2029-07-16next 2029-07-24next 2029-08-14next 2029-08-21next 2029-09-07next 2029-10-26next 2029-11-09next 2030-04-02next 2030-04-08next 2030-04-30next 2030-06-03next 2030-07-12next 2030-09-26next 2030-12-04next 2031-03-03next 2031-03-04next 2031-03-14next 2031-05-09next 2031-05-31next 2031-09-15next 2032-03-25next 2032-03-29next 2032-06-08next 2032-07-16next 2033-02-23next 2036-02-22
NVSEF
Novartis Pharmaceuticalsdistress 3/10 · well-funded / low risk$153.01+0%today-11% from 52w high
Immunology / Inflammation 1
Lead: Advanced HR+/HER2- Breast Cancer · est. market ~$35B (approx, global)
Revenue
$13524M
Liquidity
$9408M
Runway
—
Shares 1y
0%
Price & events
+2.5% over 6M
CatalystRating changeDilutionFinancingdashed = today
+0.0%
1D
+4.7%
1W
+8.5%
1M
+5.2%
3M
+2.5%
6M
+33.6%
1Y
+53.4%
2Y
+110.0%
5Y
+106.0%
All
Overview
- Market Cap
- $291.97B
- Enterprise Value
- $322.54B
- Volume
- 7.20K
- 52 Week Range
- $111 – $171
- Total Shares
- 1.91B
- Float Shares
- 1.85B
- % Held by Insiders
- 2.11%
- % Held by Institutions
- 46.24%
- RVOL
- 0.95x
- Beta
- 0.49
Pipeline stages · 47 programs
AMO959, Enzalutamide, Abiraterone
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
iptacopan
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Tisagenlecleucel, Lenalidomide and rituximab (R2) in 28-day cycles for up to 12 cycles, Ri
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Alpelisib, Fulvestrant, Trastuzumab
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pelacarsen (TQJ230)
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
VHB937
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
ECI830, ribociclib, fulvestrant
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
AAA817, ARPI
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Ofatumumab, Tetanus toxoid (TT) containing vaccine (Td, Tdap)
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
[68Ga]Ga-NeoB, [177Lu]Lu-NeoB, Capecitabine
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Show all 47 programs · 37 more ▾
rapcabtagene autoleucel (YTB323)
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
[177Lu]Lu-DWJ155
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
AAA617, Gonadotropin-releasing hormone (GnRH) analogues, Gonadotropin-releasing hormone (G
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
GHZ339
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
LTP
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Octreotide LAR
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
QVM149, Salmeterol Xinafoate / Fluticasone Propionate, Run-In Medication
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
ABL001/Asciminib
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Crizanlizumab
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Opnurasib, TNO155, trametinib
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Votoplam
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Remibrutinib
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
VAY736
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
FWY003
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Ribociclib
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
YTB323
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Tulmimetostat, Darolutamide, Abiraterone
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Remibrutinib (blinded), Remibrutinib (Open label)
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Ianalumab, Eltrombopag
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
PDR001
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
INR731, Enzalutamide, Abiraterone
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
zigakibart
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
onasemnogene abeparvovec
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
LNP023
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
DJI136
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
225Ac-ETN029, 111In-ETN029
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
DFT383
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
GVV858, Fulvestrant, Letrozole
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
QCZ484
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Atrasentan
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Inclisiran
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
JSB462, Abiraterone, Enzalutamide
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
IEV407, Fulvestrant, Letrozole
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Iptcaopan 200 mg
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Asciminib Adult formulation, Asciminib Pediatric formulation, Dexamethasone
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Previously treated CAR-T patients
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 80 trials · 80 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2028-07-10 Estimated 50% readout ~2028-08-24 | Phase 1/2 | AMO959, Enzalutamide, Abiraterone | PSMA-positive Metastatic Castration Resistant Prostate Cancer (mCRPC) With Prior Exposure to One Prior ARPI Who Are Candidates for Taxane-based Chemotherapy | — | recruiting |
| 2028-07-21 Estimated 50% readout ~2028-10-04 | Phase 3 | Iptacopan | Atypical Hemolytic Uremic Syndrome | — | recruiting |
| 2028-07-25 Estimated 50% readout ~2028-10-08 | Phase 3 | Tisagenlecleucel, Lenalidomide and rituximab (R2) in 28-day cycles for up to 12 cycles, Ri | Follicular Lymphoma (FL) | — | active not recruiting |
| 2028-08-02 Estimated 50% readout ~2028-09-16 | Phase 2 | Alpelisib | PIK3CA-related Overgrowth Spectrum (PROS) | — | recruiting |
| 2028-08-24 Estimated 50% readout ~2028-11-07 | Phase 3 | Pelacarsen | Hyperlipoproteinemia (a) | — | active not recruiting |
Show all 80 trials · 75 more ▾
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2028-09-14 Estimated 50% readout ~2028-10-29 | Phase 2 | VHB937 | Alzheimer's Disease | — | recruiting |
| 2028-09-25 Estimated 50% readout ~2028-11-09 | Phase 1/2 | ECI830, ribociclib, fulvestrant | Advanced HR+/HER2- Breast Cancer, Advanced CCNE1-amplified Solid Tumors | — | recruiting |
| 2028-09-29 Estimated 50% readout ~2028-12-13 | Phase 3 | AAA817, ARPI | Prostate Cancer | — | recruiting |
| 2028-09-30 Estimated 50% readout ~2028-12-14 | Phase 3 | Ofatumumab, Tetanus toxoid (TT) containing vaccine (Td, Tdap) | Relapsing Multiple Sclerosis | — | active not recruiting |
| 2028-10-27 Estimated 50% readout ~2029-01-10 | Phase 3 | iptacopan | IC-MPGN | — | recruiting |
| 2028-10-31 Estimated 50% readout ~2028-11-30 | Phase 1 | [68Ga]Ga-DWJ155 | Breast Neoplasms, Carcinoma, Non-Small-Cell Lung | — | recruiting |
| 2028-11-01 Estimated 50% readout ~2028-12-16 | Phase 1/2 | Rapcabtagene autoleucel | Rheumatoid Arthritis (RA) and Sjögren's Disease (SjD) | — | recruiting |
| 2028-11-08 Estimated 50% readout ~2028-12-08 | Phase 1 | [177Lu]Lu-NeoB, [68Ga]Ga-NeoB | Newly Diagnosed and Recurrent Glioblastoma | — | active not recruiting |
| 2028-11-24 Estimated 50% readout ~2028-12-24 | Phase 1 | AAA617, Gonadotropin-releasing hormone (GnRH) analogues, Gonadotropin-releasing hormone (G | Metastatic Castration-Resistant Prostate Cancer | — | recruiting |
| 2028-11-27 Estimated 50% readout ~2029-01-11 | Phase 2 | GHZ339 | Atopic Dermatitis | — | recruiting |
| 2028-11-29 Estimated 50% readout ~2029-01-13 | Phase 1/2 | LTP | Healthy Volunteers, Pulmonary Arterial Hypertension | — | recruiting |
| 2028-11-30 Estimated 50% readout ~2029-01-14 | Phase 2 | rapcabtagene autoleucel, rituximab | Scleroderma, Diffuse | — | recruiting |
| 2028-12-07 Estimated 50% readout ~2029-02-20 | Phase 3 | Pelacarsen | Acute Coronary Syndrome (ACS) | — | not yet recruiting |
| 2028-12-08 Estimated 50% readout ~2029-02-21 | Phase 3 | Octreotide LAR | Somatostatin Receptor Positive (SSTR+), Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET) | — | recruiting |
| 2028-12-21 Estimated 50% readout ~2029-03-06 | Phase 3 | QVM149, Salmeterol Xinafoate / Fluticasone Propionate, Run-In Medication | Asthma | — | not yet recruiting |
| 2029-02-17 Estimated 50% readout ~2029-04-03 | Phase 2 | ABL001/Asciminib | Chronic Myeloid Leukemia (CML) | — | recruiting |
| 2029-03-09 Estimated 50% readout ~2029-04-23 | Phase 2 | Rapcabtagene autoleucel | Idiopathic Inflammatory Myopathies | — | active not recruiting |
| 2029-03-09 Estimated 50% readout ~2029-04-23 | Phase 1/2 | [177Lu]Lu-DOTA-TATE, Atezolizumab, [68Ga]Ga-DOTA-TATE | Extensive Stage Small Cell Lung Cancer | — | active not recruiting |
| 2029-03-23 Estimated 50% readout ~2029-06-06 | Phase 3 | Crizanlizumab | Sickle Cell Disease | — | recruiting |
| 2029-04-16 Estimated 50% readout ~2029-06-30 | Phase 3 | Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL | Primary Prevention of Atherosclerotic Cardiovascular Disease | — | active not recruiting |
| 2029-05-09 Estimated 50% readout ~2029-06-08 | Phase 1 | 68Ga-NNS309, 177Lu-DFC413 | Pancreatic Ductal Adenocarcinoma, Non-Small Cell Lung Cancer, HR+/HER2- Ductal and Lobular Breast Cancer, Triple Negative Breast Cancer, Colorectal Cancer, Soft Tissue Sarcoma | — | recruiting |
| 2029-06-07 Estimated 50% readout ~2029-07-22 | Phase 2 | Rapcabtagene autoleucel, Glucocorticoids | ANCA Associated Vasculitis (AAV) | — | recruiting |
| 2029-06-15 Estimated 50% readout ~2029-07-30 | Phase 1/2 | Opnurasib, TNO155, trametinib | Locally Advanced or Metastatic KRAS G12C-mutated Non-small Cell Lung Cancer, Advanced Solid Tumors Harboring the KRAS G12C Mutation | — | recruiting |
| 2029-07-16 Estimated 50% readout ~2029-08-30 | Phase 2 | Votoplam | Huntington Disease | — | active not recruiting |
| 2029-07-20 Estimated 50% readout ~2029-10-03 | Phase 3 | — | Progressive Supranuclear Palsy Richardson Syndrome (PSP-RS) | — | recruiting |
| 2029-07-24 Estimated 50% readout ~2029-10-07 | Phase 3 | Remibrutinib oral treatment, Ocrelizumab | Relapsing Multiple Sclerosis | — | recruiting |
| 2029-08-14 Estimated 50% readout ~2029-10-28 | Phase 3 | VAY736 | Sjögren´s Disease | — | not yet recruiting |
| 2029-08-21 Estimated 50% readout ~2029-10-05 | Phase 2 | FWY003 | Geographic Atrophy Secondary to Age-related Macular Degeneration | — | recruiting |
| 2029-09-07 Estimated 50% readout ~2029-11-21 | Phase 3 | Ribociclib, Letrozole, Ansastrozole | Early Breast Cancer | — | recruiting |
| 2029-10-26 Estimated 50% readout ~2029-12-10 | Phase 1/2 | YTB323 | Generalized Myasthenia Gravis | — | recruiting |
| 2029-11-09 Estimated 50% readout ~2029-12-24 | Phase 1/2 | Tulmimetostat DL1 QD, Tulmimetostat DL2 QD, Tulmimetostat DL3 QD | Progressive Metastatic Castrate Resistant Prostate Cancer | — | recruiting |
| 2030-01-09 Estimated 50% readout ~2030-03-25 | Phase 3 | Pelacarsen (TQJ230) | Cardiovascular Disease and Lipoprotein(a) | — | recruiting |
| 2030-02-27 Estimated 50% readout ~2030-04-13 | Phase 1/2 | Tulmimetostat, Enzalutamide | Advanced Solid Tumor, Diffuse Large B Cell Lymphoma, Lymphoma, T-Cell, Mesothelioma, Malignant, Prostatic Neoplasms, Castration-Resistant, Endometrial Cancer, Ovarian Clear Cell Carcinoma, Metastatic Castration-resistant Prostate Cancer | — | recruiting |
| 2030-03-12 Estimated 50% readout ~2030-04-26 | Phase 2 | Pelacarsen (TQJ230) 80mg | Aortic Stenosis | — | recruiting |
| 2030-04-02 Estimated 50% readout ~2030-06-16 | Phase 3 | Votoplam (blinded) | Huntington Disease | — | recruiting |
| 2030-04-08 Estimated 50% readout ~2030-06-22 | Phase 3 | Ianalumab | Systemic Lupus Erythematosus | — | recruiting |
| 2030-04-30 Estimated 50% readout ~2030-05-30 | Phase 1 | PDR001 | Advanced Solid Tumors | — | active not recruiting |
| 2030-05-29 Estimated 50% readout ~2030-08-12 | Phase 3 | Ribociclib | Early Breast Cancer | — | active not recruiting |
| 2030-06-03 Estimated 50% readout ~2030-07-03 | Phase 1 | INR731, Enzalutamide, Abiraterone | Metastatic Castration-resistant Prostate Cancer (mCRPC) | — | recruiting |
| 2030-06-14 Estimated 50% readout ~2030-07-29 | Phase 1/2 | rapcabtagene autoleucel (YTB323) | Progressive Multiple Sclerosis | — | recruiting |
| 2030-06-28 Estimated 50% readout ~2030-09-11 | Phase 3 | iptacopan | Primary Immunoglobulin A Nephropathy (IgAN) | — | recruiting |
| 2030-07-12 Estimated 50% readout ~2030-08-26 | Phase 2 | zigakibart | Immunoglobulin A Nephropathy (IgAN) | — | recruiting |
| 2030-07-16 Estimated 50% readout ~2030-09-29 | Phase 3 | Ianalumab | Lupus Nephritis | — | recruiting |
| 2030-08-30 Estimated 50% readout ~2030-10-14 | Phase 2 | Ianalumab | Primary Immune Thrombocytopenia, Warm Autoimmune Hemolytic Anemia | — | recruiting |
| 2030-09-26 Estimated 50% readout ~2030-12-10 | Phase 3 | onasemnogene abeparvovec | Spinal Muscular Atrophy (SMA) | — | recruiting |
| 2030-10-01 Estimated 50% readout ~2030-11-15 | Phase 1/2 | rapcabtagene autoleucel (YTB323) | Relapsing Multiple Sclerosis | — | recruiting |
| 2030-12-03 Estimated 50% readout ~2031-02-16 | Phase 3 | Remibrutinib (blinded), Remibrutinib (Open label) | Secondary Progressive Multiple Sclerosis (SPMS) | — | recruiting |
| 2030-12-04 Estimated 50% readout ~2031-02-17 | Phase 3 | LNP023 | Primary IgA Nephropathy | — | active not recruiting |
| 2030-12-08 Estimated 50% readout ~2031-02-21 | Phase 3 | Pelacarsen (TQJ230) | Atherosclerotic Cardiovascular Disease | — | recruiting |
| 2031-01-15 Estimated 50% readout ~2031-02-14 | Phase 1 | [68Ga]Ga-NNS309, [177Lu]Lu-NNS309 | Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer, HR+/HER2- Ductal and Lobular Breast Cancer, Triple Negative Breast Cancer, Colorectal Cancer | — | recruiting |
| 2031-03-03 Estimated 50% readout ~2031-04-17 | Phase 1/2 | DJI136 | Extensive-stage Small Cell Lung Cancer (ES-SCLC) | — | recruiting |
| 2031-03-04 Estimated 50% readout ~2031-04-03 | Phase 1 | 225Ac-PSMA-R2 | Prostate Cancer | — | active not recruiting |
| 2031-03-14 Estimated 50% readout ~2031-04-28 | Phase 1/2 | DFT383 | Nephropathic Cystinosis | — | recruiting |
| 2031-05-09 Estimated 50% readout ~2031-06-23 | Phase 1/2 | GVV858, Fulvestrant, Letrozole | Advanced HR+/HER2- Breast Cancer, Advanced CCNE1-amplified Solid Tumors, Metastatic Castration-resistant Prostate Cancer | — | recruiting |
| 2031-05-31 Estimated 50% readout ~2031-07-15 | Phase 2 | QCZ484 | Hypertension (HTN) | — | recruiting |
| 2031-06-25 Estimated 50% readout ~2031-09-08 | Phase 3 | zigakibart | Kidney Diseases, Kidney Diseases, Chronic, Urological Diseases, Glomerulonephritis, Glomerular Disease, Glomerulonephritis, IGA, Glomerulopathy, Immunoglobulin Disease | — | recruiting |
| 2031-06-27 Estimated 50% readout ~2031-08-11 | Phase 2 | Alpelisib, Fulvestrant, Trastuzumab | PIK3CA-Related Overgrowth Spectrum (PROS), Breast Neoplasms (Including Advanced or Metastatic Breast Cancer With PIK3CA Mutation) | — | not yet recruiting |
| 2031-08-29 Estimated 50% readout ~2031-09-28 | Phase 1 | 225Ac-ETN029, 111In-ETN029 | Small Cell Lung Carcinoma, Large Cell Neuroendocrine Carcinoma of the Lung, Neuroendocrine Prostate Cancer, Gastroenteropancreatic Neuroendocrine Carcinoma | — | recruiting |
| 2031-09-09 Estimated 50% readout ~2031-10-24 | Phase 1/2 | [68Ga]Ga-NeoB, [177Lu]Lu-NeoB, Capecitabine | Breast Cancer | — | active not recruiting |
| 2031-09-15 Estimated 50% readout ~2031-11-29 | Phase 3 | Atrasentan | Berger Disease, Bergers Disease, IgA Nephropathy, Immunoglobulin A Nephropathy, Primary IgAN, Nephritis IgA Type, Nephropathy IgA Type | — | not yet recruiting |
| 2031-10-27 Estimated 50% readout ~2032-01-10 | Phase 3 | Remibrutinib | Hidradenitis Suppurativa | — | not yet recruiting |
| 2031-11-19 Estimated 50% readout ~2032-02-02 | Phase 3 | LNP023 | Paroxysmal Nocturnal Hemoglobinuria (PNH) | — | recruiting |
| 2032-03-25 Estimated 50% readout ~2032-06-08 | Phase 3 | Inclisiran | Heterozygous or Homozygous Familial Hypercholesterolemia | — | recruiting |
| 2032-03-29 Estimated 50% readout ~2032-05-13 | Phase 2 | JSB462, Abiraterone, Enzalutamide | Metastatic Hormone-sensitive Prostate Cancer | — | recruiting |
| 2032-05-24 Estimated 50% readout ~2032-06-23 | Phase 1 | [177Lu]Lu-DWJ155 | Breast Cancer, Non-small Cell Lung Cancer (NSCLC), Gastric/Gastroesophageal Junction (GEJ) Cancer, Bladder Cancer | — | recruiting |
| 2032-06-08 Estimated 50% readout ~2032-07-08 | Phase 1 | IEV407, Fulvestrant, Letrozole | Advanced HR+/HER2- Breast Cancer | — | recruiting |
| 2032-07-16 Estimated 50% readout ~2032-09-29 | Phase 3 | Iptcaopan 200 mg | Atypical Hemolytic Uremic Syndrome | — | recruiting |
| 2032-08-02 Estimated 50% readout ~2032-09-16 | Phase 1/2 | Tulmimetostat, Darolutamide, Abiraterone | Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) | — | recruiting |
| 2033-01-30 Estimated 50% readout ~2033-04-15 | Phase 3 | Remibrutinib | Indication of the Parent Protocol | — | recruiting |
| 2033-02-23 Estimated 50% readout ~2033-04-09 | Phase 2 | Asciminib single agent | Chronic Myelogenous Leukemia, Leukemia, Myelogenous, Chronic, Philadelphia Chromosome Positive | — | recruiting |
| 2033-04-22 Estimated 50% readout ~2033-06-06 | Phase 2 | Ianalumab, Eltrombopag | Primary Immune Thrombocytopenia (ITP) | — | not yet recruiting |
| 2033-04-22 Estimated 50% readout ~2033-07-06 | Phase 3 | Ianalumab (VAY736) | Sjogrens Syndrome | — | active not recruiting |
| 2033-07-18 Estimated 50% readout ~2033-09-01 | Phase 1/2 | Asciminib Adult formulation, Asciminib Pediatric formulation, Dexamethasone | Acute Lymphoblastic Leukemia, Leukemia, Lymphoblastic, Acute, Philadelphia-Positive, Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia | — | not yet recruiting |
| 2036-02-22 Estimated 50% readout ~2036-05-07 | Phase 3 | Previously treated CAR-T patients | Long Term Safety of Patients Receiving CAR-T in an Eligible Clinical Trial or Managed Access Program | — | recruiting |
| 2036-05-30 Estimated 50% readout ~2036-08-13 | Phase 3 | LNP023 | C3 Glomerulopathy, Immune-complex-membranoproliferative Glomerulonephritis | — | recruiting |
Catalyst news & presentations · 0
- No catalyst news yet.
Approved drugs (14)
- RHAPSIDOREMIBRUTINIB2025 · Prescription
- VANRAFIAATRASENTAN HYDROCHLORIDE2025 · Prescription
- VIJOICEALPELISIB2024 · Prescription
- ENTRESTO SPRINKLESACUBITRIL2024 · Prescription
- FABHALTAIPTACOPAN HYDROCHLORIDE2023 · Prescription
- COSENTYXSECUKINUMAB2023 · Prescription
- MEKINISTTRAMETINIB2023 · Prescription
- TAFINLARDABRAFENIB MESYLATE2023 · Prescription
- VIJOICEALPELISIB2022 · Prescription
- PLUVICTOLUTETIUM LU-177 VIPIVOTIDE TETRAXETAN2022 · Prescription
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
no consensus
- no recent rating changes
Competitors — Advanced HR+/HER2- Breast Cancer
- none identified
Recent news
- 2026-07-23Novartis stock trades steady as Q1 2026 revenue grows and Cosentyx expansion supports outlook - Ad-hoc-news.de
- 2026-07-22Novartis Q2 sales strong in oncology, upgrades stock rating to buy despite Entresto decline - Pluang
- 2026-07-21Novartis stock steadies as Cosentyx growth and productivity plan shape the outlook - Ad-hoc-news.de
- 2026-07-21Why Novartis CEO ended his ADC holdout for $1.5B Myricx deal - Fierce Biotech
- 2026-07-21For Novartis' CEO, China deals aren't a strategy shift — just where the science is - Endpoints News
- 2026-07-21Novartis second quarter sales rise 3% to $14.4 billion - grafa.com
- 2026-07-21Novartis CEO brushes off oral PCSK9 competition as Leqvio drives Q2 growth - Fierce Pharma
- 2026-07-21Novartis Q2 2026 earnings beat as cancer, MS drugs drive growth - qz.com
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.